78
INTRODUCTION
The diagnosis of brain metastases (BM) is frequently related to the natural history of the spread of many primary tumors including those arising in the lung, breast, colorectal, renal, and skin (i.e. melanoma) [1] . Development of metastatic disease in the brain can lead to clinically significant reductions in health-related quality-of-life, neurological/neurocognitive compromise, and life expectancy [2] . Treatment selection is highly dependent on pretreatment clinical factors, prognosis -as estimated by various published risk stratification prognostic indices, and patient treatment preferences [3, 4] .
A published randomized controlled trial (RCT) comparing whole brain radiotherapy (WBRT) plus stereotactic radiotherapy (SRS) boost versus WBRT alone supports the use of the SRS technique in oligometastatic (1-3 brain metastases, ≤3.0 cm) patients [5] . This clinical trial demonstrated clinically important improvements in lesion control, performance status, and survival (in the solitary metastasis subgroup). Subsequent published RCTs have addressed the issue of whether or not the WBRT component is advisable for the initial treatment of de novo brain metastases [6] [7] [8] [9] . In general, inclusion of WBRT has been shown to improve regional intracranial control but at the expense of additional neurocognitive effects.
Durable lesion control, ideally lasting during the expected patient lifespan, is an important goal of high-quality SRS in order to prevent symptomatic recurrence that would mandate consideration of one or more salvage procedures including WBRT, neurosurgical resection, and various forms of drug therapy [10] . Various investigations have been published on the topic of predictive factors associated with lesion control in the context of SRS treatment [11] [12] [13] [14] [15] [16] [17] [18] . Factors that have been shown in at least one publication to be a significant predictor of lesion control include: lesion dose, lesion radiological characteristics (i.e. lesion aspect), lesion target volume, patient performance status, presence of extracranial disease, cancer histology, and inclusion of WBRT.
The objective of this investigation is to identify independent pretreatment factors that predict for lesion control in the context of a large single institution SRS brain metastases series. Recursive partitioning analysis will be used to potentially identify a class of patients with durable lesion control characteristics. Our findings will be discussed in the context of previously published investigations.
METHODS AND MATERIALS

SRS Database
The SRS database contains baseline characteristics, treatment details, and follow-up data of newly diagnosed BM patients treated with Linac-based SRS. Patients with newly-diagnosed high resolution contrast-enhanced MRI confirmed 1-3 BM (including those near brainstem and posterior fossa) were eligible for single modality SRS. Patients with recurrent disease after previous radiotherapy were not included in this series. SRS has been delivered using 5 dynamic conformal arcs either on a Novalis volumes consisted outer contrast-enhancing border of the lesions contoured on the planning MRI with a 1mm margin to correct for residual setup error. All lesion target volumes were prescribed to the 80% isodose line. SRS was generally prescribed using a prospectively defined 'risk-adapted' fractionation scheme; with the smallest lesions (≤7.5cm3) receiving 21Gy, lesions measuring 7.5-25cm3 or those BM adjacent to the brainstem receiving 18Gy, and the largest lesions (>25cm3) utilizing either a single fraction of 15Gy or 24Gy in 3 fractions of 8Gy. The prescription dose was always determined after contouring the target volume in the planning system. As brain metastases are often spherical, the 21 Gy cutoff value generally corresponds to lesions with a max diameter of approximately 2.5 cm, and the 18 Gy cutoff value corresponds to lesion of approximately 3.6 cm.
Recommended follow-up for SRS patients consisted of clinic visits including neurological examination with contrast-enhanced MRI every three months during the first two years, followed by 6-monthly clinic visits and MRI scans thereafter. The median follow-up duration of the database calculated using the reverse Kaplan-Meier method was 32 months [19] .
Lesional aspect was classified based on the pattern of contrast enhancement on gadoliniumenhanced T1 sequences of the MRI, as was previously described by Goodman et al. [18] . Lesions were classified as: 1) lesions with homogeneous (i.e. uniform) contrast enhancement, 2) lesions with heterogeneous contrast enhancement, if there were areas of non-homogeneous contrast enhancement, 3) thin walled cystic lesions (either simple cystic or multicystic), and 4) lesions with a necrotic center.
Radiological evidence of lesional progressive disease was defined according to the criteria described by Shiau et al. [17] and specifically was defined as "at least 25% increase in the product of three perpendicular diameters (craniocaudal, anterior-posterior and mediolateral)". Date of death and intracranial and extracranial disease status at time of death was also captured in the retrospective database.
Endpoints
Three separate endpoints were utilized in conjunction with this predictive analysis:
1.
Time to Progression (n=536 lesions), Primary Endpoint. Defined as time from initiation of stereotactic radiosurgery to development of progressive disease on a per-lesion level. Each lesion was evaluated according to the follow-up guidelines (see above) to determine whether or not radiological and/or clinical evidence of progressive disease was indeed present (yes/no) as well as the date of evaluation.
2.
Time to First Progression (n=380 patients), Secondary Endpoint. This endpoint was derived from the "time to progression" endpoint at a per-patient level. Patients were first evaluated as having either progressive intracranial disease at any lesion/site (yes/no) then further evaluated to determine in which lesion(s) progression FIRST occurred (if two or three lesions showed progression at same time, the largest lesion was used in final analysis) [20] . This time to first progression analysis was performed to further assess the stability of findings from the primary time to progression (per lesion) analysis (see 1 above) in terms of possible non-independence issues resulting from the inclusion of more than one lesion per patient.
3.
Survival (n=380 patients), Secondary Endpoint. Defined as time from initiation of stereotactic radiosurgery to date of last follow-up and/or death whichever came first. This endpoint was reported for descriptive purposes only and was not used for any predictive modeling.
Statistical Methodology
Univariable Cox regressions were constructed for time to progression (Model 1) and time to first progression (Model 2) to identify significant predictors of progressive disease which was performed at the lesion level (n=536) and patient level (n=380), respectively. Multivariable cox regression analyses were performed, incorporating all factors found to be somewhat significant from univariable cox regression (i.e. p < 0.30), followed by automated backward elimination technique to sequentially remove factors until all remaining covariates had p-values less than 0.15. Adjustment for clustering was performed for univariable and multivariable analyses related to time to progression due to the fact that each patient contributed different numbers of lesions to the analysis.
Recursive partitioning analysis (RPA) was performed at the lesion level (n=536), incorporating significant predictors identified from multivariable cox regression (Model 1 factors: lesion radiological phenotype (aspect) and radiation dose) [21] . The SRS lesion RPA was performed in two ways: (1) primarily as a time-to-event outcome (taking into account 'time' to progressive disease) and (2) modelling progressive disease as a binary outcome (yes/no) to assess the robustness of the SRS lesion RPA model created. Kaplan-Meier estimates of time to progression (n=536) and time to first progression (n=380) were performed. Kaplan-Meier estimates stratified by baseline characteristics and proposed SRS lesion RPA stratifications were also calculated (for all three endpoints including overall survival) and different classes were compared using log-rank test statistic. Statistical analysis was performed using SAS (version 9.2, SAS Institute Inc., Cary, NC, USA and the open source R software platform (www.rproject.org). Results from the univariable Cox regression analysis for both the lesional (time to progression analysis) and patient (time to first progression) analyses are depicted in Table 2 . Results of multivariable Cox regression analysis for both time to progression and time to first progression are summarized in Supplemental Tables 3 and 4 , respectively (available at http://theoncologist.alphamedpress.org). Both models demonstrate that lesion aspect/phenotype and RT schedule are independent factors associated with both progression outcomes. Presence of tumor necrosis was found to be associated with a significant hazard of progression (hazard ratio >3) whereas use of the most intense radiotherapy fractionation schedule (21Gy/1fraction) was associated with significant reductions in progression (hazard ratio <0.3). Kaplan-Meier curves for all eligible patients and subdivided into relevant groups for both progression outcomes are summarized in supplemental Figure e1 (theoncologist.alphamedpress.org). As depicted in Figure 2 , SRS lesion RPA time-to-event and binary analyses partitioned the patient population into four possible groupings based on RT schedule (21Gy/1 fraction vs. other less BED intense regimens) and lesion aspect/phenotype (different combinations observed; however the 21Gy/1 fraction arm was split identically between homogeneous/heterogeneous vs. cystic/necrotic). KaplanMeier curves for each of the SRS lesion RPA groups were created for both progression outcomes using both RPA approaches (time-to-event and binary, Figure 3) . Inspection of these Kaplan-Meier depictions, demonstrate that three distinct groups of patients are present (a good prognosis group -group 1, and intermediate group consisting of the two middle SRS lesion RPA groups 2/3, and a poor prognosis group -group 4). Individual Kaplan-Meier progression curves for each aspect/phenotype combination with 21Gy/1 fraction versus other fractionation schedule are shown in Figure 4 . Figure 5 summarizes the Kaplan-Meier overall survival curves for all patients and curves divided by lesion/aspect and highest radiation BED fractionation. Kaplan-Meier overall survival estimates were affected by SRS lesion RPA group with a statistically significant log-rank test (p=0.05) in terms of overall survival. 
RESULTS
Between
DISCUSSION
This report has summarized the progression and survival outcomes of a large SRS database with a particular focus on the determination of factors that predict for brain metastasis local lesion control.
Lesion aspect/phenotype and radiation dose schedule were both found to be critical independent factors both in the prediction of time to lesion progression and also time to first lesion progression at the patient level. Presence of extracranial disease was found to have a borderline significant effect on radiological confirmation of lesional progression. This may be due to a confounding effect in which patients with extracranial disease may suffer from extracranial progression and death prior to intracranial lesion progression. Regine et al. have previously observed this relationship in a thirty-six patient cohort in which presence of extracranial disease reduced the rate of observed symptomatic brain recurrence by more than half [13] . Tumour histology was not found to inform the SRS lesion RPA despite statistical significance on univariable analysis. It is hypothesized that in the context of SRS dosing, histology may not be important given the ablative doses being utilized, and/or that the prognostic impact of histology may be exerted indirectly through lesion phenotype (i.e. necrotic lesions) having inferior local control.
control. Similarly, Schomas et al. [14] observed that dose prescription, minimum tumor dose, histology as well as tumor volume were predictive of local control on univariable analysis. Minimum tumor dose was the only factor predictive of local control on multivariable analysis (p=0.03). Molenaar et al. have also observed that SRS dose, planning target volume, and patient performance status were predictive of time to local failure [12] . Shetata et al. suggested that the use of whole-brain radiation therapy in conjunction with SRS improved lesion control [15] however this claim has not been reported elsewhere in literature. A systematic review formally exploring the relationship between dose and local control has been recently published by Wiggenraad et al. [16] . This review assessed eleven papers and demonstrated that six-month local control was greater than 80% irrespective of SRS dose fractionation schedule. Oneyear local control rates with single dose SRS treatment was observed to be more variable and depended on dose: >80% (≥ 21Gy), >60% (≥ 18Gy), <50% (<15Gy).
The major limitation of this work is that the database is derived from a retrospective analysis of SRS patients. Mitigating the issue of the retrospective nature of the database was the prospective approach regarding patient selection, treatment simulation/delivery, dose-fractionation selection, and follow-up procedures relating to this patient population. Future work in this area will include validation of our findings in other existing SRS databases. Additionally, modeling of regional (out-of-field) failure risk may provide insight into patients better served with the integration of whole brain radiation therapy in conjunction with SRS therapy.
CONCLUSIONS
A recursive partitioning analysis of a large retrospective SRS database has confirmed previous observations regarding the importance of SRS dose and lesion aspect/phenotype in lesion control. The SRS lesion RPA describes three distinct prognostic groups of patients in terms of time to lesion progression. Use of the SRS lesion RPA groups also predicted for overall survival using an actuarial logrank test analysis. The SRS lesion RPA analysis may assist in stratification of future SRS clinical trials as well as better defining patient care options and prognosis in conjunction with SRS therapy.
